This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other schizoaffective disorders기타 조현정동장애 (기타분열정동장애)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: F25.8 (other schizoaffective disorders) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduced for 5 years after registration)
B. SynonymsOther schizoaffective disorder; no synonyms designated (residual category including other specified schizoaffective clinical presentations)
C. Adult onsetLikelihood of first onset in adulthood: high - because these are schizoaffective presentations not falling under F25.0-F25.2, the age-of-onset range is somewhat broad, but onset typically occurs in adulthood (20s-40s) in many cases.
1. HistorySet as an ICD-10 residual category code; includes schizoaffective cases that do not meet the typical criteria of F25.0-F25.2; subtype classification system under review in the ICD-11 revision process; may include schizoaffective cases in special clinical situations (perinatal, elderly, adolescent).
2. CausesSame multifactorial etiology as F25.0-F25.2 (genetic predisposition, neurotransmitter abnormalities, neurodevelopmental abnormalities, environmental factors); additional causal factors possible depending on special clinical situations (perinatal, late-life onset, adolescent onset).
3. GeneticsEssentially the same genetic architecture as F25.0-F25.2; shared genetic spectrum of schizophrenia and mood disorders; possible genetic basis for phenotypic variability not classified into a specific subtype.
4. General epidemiologyEpidemiologic data for the F25.8 code alone are limited; estimated at less than about 5% of all schizoaffective disorders; includes perinatal psychosis, late-life onset, and atypical clinical courses; a residual group that is difficult to classify accurately.
5. PathophysiologyEssentially shares the pathophysiology of F25.0-F25.2; additional mechanisms possible depending on special clinical situations (perinatal hormonal changes, aging-related brain changes, neurobiological changes related to medical comorbidities).
6. SymptomsClinical presentations in which schizophrenia symptoms and mood episodes coexist but do not meet the typical criteria of F25.0-F25.2; mood episodes that are brief or atypical; may include schizoaffective disorder with hypomania, schizoaffective disorder with catatonia, etc.
7. SignsClinical signs equivalent to F25.0-F25.2; because of atypicality, application of rating scales may be incomplete; reconfirming organic causes and longitudinal reassessment are especially important.
8. ScreeningSame screening principles as F25.0-F25.2; exclusion of organic causes is performed more actively in atypical clinical presentations; brain MRI, EEG, autoimmune panel, and endocrine tests to be considered first.
9. DiagnosisF25.8 is assigned when the F25.0-F25.2 criteria have been reviewed and found not to fit; use the code together with as detailed a clinical description as possible; a useful residual code when using ICD-10; longitudinal follow-up is needed for the possibility of future reclassification to F25.0-F25.2.
10. TreatmentFollowing the treatment principles of F25.0-F25.2, apply antipsychotics, mood stabilizers, and antidepressants according to the main symptom type; dose adjustment and safety considerations suited to special clinical situations (pregnancy, elderly, adolescent) are essential.
11. PrognosisPrognosis is difficult to predict because of the atypical clinical presentation and classification uncertainty; a similar treatment response can be expected when treatment equivalent to the typical subtypes is applied; subtype reclassification is possible over the longitudinal course.
12. PreventionSame prevention principles as F25.0-F25.2; maintenance therapy for relapse prevention; suicide prevention safety plan; development of a tailored prevention plan suited to the special clinical situation.
13. ReferencesMalaspina D, et al. Schizoaffective disorder in the DSM-5. Schizophr Res. 2013 … and 9 other papers

1. History

Other schizoaffective disorder (F25.8) is a residual category code established in the ICD-10 classification system to include schizoaffective clinical phenotypes that do not fall under F25.0 (manic type), F25.1 (depressive type), or F25.2 (mixed type). This code is used to classify cases in which coexistence of schizophrenia symptoms and mood episodes is confirmed but which do not clearly fit the criteria of the three existing typical subtypes.

Historically, the subtype classification of schizoaffective disorder has developed over several decades since Kasanin's first description in 1933 to cover diverse clinical phenotypes. In clinical reality, however, there are cases that cannot be clearly classified into the three subtypes of manic, depressive, and mixed type, and the F25.8 code was established in ICD-10 in response. This was a pragmatic decision to secure clinical practicality while acknowledging the limitations of the classification system.

Clinical situations to which the F25.8 code may apply include the following. First, perinatal schizoaffective cases: schizoaffective symptoms occurring in the peripartum period, in which hormonal changes and sleep deprivation may cause atypical manifestations of mood episodes and psychotic symptoms. Second, late-onset schizoaffective cases: schizoaffective presentations first arising after age 50, in which differentiation from neurodegenerative disease and cerebrovascular disease is important. Third, schizoaffective cases with hypomania: cases in which a hypomanic episode, rather than a manic episode, coexists with schizophrenia symptoms and may not fully meet the F25.0 criteria of ICD-10. Fourth, cases not meeting the duration criterion for mood episodes: cases in which the duration of the mood episode is relatively short compared with the duration of psychotic symptoms.

ICD-11 (2022) re-examined the subtype classification of schizoaffective disorder. ICD-11 retains a single-episode-based classification while allowing more flexible clinical description through course specifiers. These changes may act to reduce the need for residual categories such as F25.8.

In Korean clinical practice, the F25.8 code is used for schizoaffective clinical phenotypes that are difficult to classify into the typical subtypes, and registration for Special Copayment Reduction V161 is possible. After the initial F25.8 diagnosis, cases are often reclassified to F25.0, F25.1, or F25.2 through longitudinal follow-up, so regular diagnostic reassessment is essential.

From a taxonomic perspective, residual categories such as F25.8 expose the incompleteness of psychiatric classification systems while reflecting a pragmatic approach that acknowledges the diversity of clinical reality. Advances in neurobiological markers and genomic research are expected to enable more precise classification of atypical schizoaffective cases in the future.


2. Causes

The causes of other schizoaffective disorder (F25.8) basically share the same multifactorial etiologic structure as F25.0-F25.2. It is based on the complex interaction of genetic predisposition, neurodevelopmental abnormalities, neurotransmitter imbalance, and environmental stressors. However, additional specific causal factors may be involved depending on the clinical situation classified as F25.8 (perinatal, late-life onset, atypical duration criteria, etc.).

Causal specificity of perinatal schizoaffective cases: In the postpartum period, hormone levels such as estrogen, progesterone, and prolactin change dramatically, which affects the dopamine and serotonin systems and increases vulnerability to the onset of psychotic symptoms and mood episodes. Sleep deprivation and postpartum stress are also important triggers. In perinatal schizoaffective cases, onset within 2-4 weeks after delivery is characteristic, and it can occur even without a prior history of schizophrenia or mood disorder.

Causal specificity of late-onset schizoaffective cases: In schizoaffective cases with first onset after the 50s-60s, the dopamine system changes of brain aging, cerebrovascular disease (white matter lesions, small infarcts), and the possibility of prodromal symptoms of neurodegenerative disease (Lewy body dementia, frontotemporal dementia) must be considered. In addition, metabolic abnormalities such as hypothyroidism, vitamin B12 deficiency, and adrenal insufficiency can cause psychosis and mood episodes in the elderly.

Schizoaffective cases with hypomania: When a hypomanic episode, rather than a typical manic episode, appears together with schizophrenia symptoms, the causes involve dopamine overactivity and mood-regulating circuit abnormalities similar to F25.0 (manic type), but with lower severity. In this case, the clinical picture lies at the border with the bipolar II disorder spectrum.

Common causal factors: Dopamine, serotonin, and glutamate system abnormalities shared with F25.0-F25.2, genetic predisposition (GWAS-shared genetic risk variants), neurodevelopmental vulnerability, psychosocial stress, and substance abuse also act as important causal factors in F25.8 cases.


3. Genetics

The genetics of other schizoaffective disorder (F25.8) share essentially the same genetic background as F25.0-F25.2 and lie on the genetic spectrum between schizophrenia and mood disorders (bipolar disorder, major depressive disorder).

Shared genetic architecture: Atypical schizoaffective clinical phenotypes classified as F25.8 are also expected to share the same genetic risk variants as the typical subtypes. The high genetic correlation among schizophrenia, bipolar disorder, and major depressive disorder in large-scale GWAS studies suggests that F25.8 cases lying at the border of these disorders also carry a complex polygenic risk burden.

Genetic basis of phenotypic variability: Even among individuals with the same genetic risk burden, clinical phenotypes can differ greatly. This phenotypic variability is explained in part by gene-environment interaction, epigenetic changes, and the influence of modifier genes. The atypical phenotypes classified as F25.8 may lie at the extreme of this phenotypic variability.

Perinatal-related genetic factors: In perinatal schizoaffective cases, interaction between estrogen receptor gene (ESR1, ESR2) polymorphisms and dopamine and serotonin system genes is being studied as a genetic factor determining vulnerability to hormonal change. The COMT Val158Met polymorphism is associated with altered dopamine metabolism when estrogen is low and may contribute to the onset of perinatal psychosis.

Genetic considerations in late-life onset: In late-onset schizoaffective cases, an association with the APOE ε4 allele (Alzheimer risk gene) has been reported in some studies, suggesting that late-life onset may be linked to neurodegenerative processes. However, the evidence for this is still limited.

Genetic counseling for patients clinically diagnosed with F25.8 follows the principles applied to schizoaffective disorder in general (explaining family risk, educating about the genetic complexity of the disease), and genetic testing specific to a particular subtype is not currently part of standard care.


4. General epidemiology

Independent epidemiologic data for other schizoaffective disorder (F25.8) are very limited. This is because F25.8 is a residual category code that includes cases not classified into the typical subtypes, and because the typical subtypes (F25.0-F25.2) are mainly used for research purposes.

Estimated prevalence: Cases classified as F25.8 are estimated at less than about 5% of all schizoaffective disorders. Given that the lifetime prevalence of schizoaffective disorder overall is about 0.3%, the prevalence of F25.8 is estimated at about 0.01-0.015%. However, this may vary greatly depending on code usage patterns in clinical practice.

Sex and age distribution: The sex and age distribution of F25.8 varies depending on the clinical situations included. Perinatal cases occur only in women, with onset within several weeks after delivery. Late-onset cases include onset after age 50. Cases with hypomania and cases with atypical duration criteria show an onset pattern in young and middle adulthood similar to typical schizoaffective disorder.

Epidemiology of perinatal schizoaffective cases: Postpartum psychosis occurs in about 1-2 per 1,000 deliveries, and some of these show a schizoaffective clinical picture. In perinatal schizoaffective cases, risk is greatly increased in women with a prior history of bipolar disorder or schizophrenia, and is also high when a first-degree relative has a history of perinatal psychosis.

Diagnostic code usage patterns: In clinical practice, the F25.8 code is often used as a provisional diagnosis in uncertain clinical situations, and a high proportion are later reclassified to typical subtypes through follow-up. Analyzing the frequency of F25.8 code use in Health Insurance Review & Assessment Service (HIRA) data could reveal actual clinical application patterns, but publicly available data on this are limited.


5. Pathophysiology

The pathophysiology of other schizoaffective disorder (F25.8) shares essentially the same neurobiological basis as the typical subtypes (F25.0-F25.2), with additional mechanisms involved depending on the specificity of the clinical situation.

Common neurobiological mechanisms: Mesolimbic dopamine overactivity (positive symptoms), prefrontal dopamine hypoactivity (negative and cognitive symptoms), serotonin system abnormalities (mood symptoms), glutamate NMDA receptor hypofunction (negative, cognitive, and psychotic symptoms), and HPA axis overactivation (stress response) also act as core mechanisms in F25.8 cases. Connectivity abnormalities of the prefrontal-limbic-striatal circuit appear across various symptom domains.

Special mechanisms of perinatal cases: The abrupt decrease in estrogen after delivery increases dopamine receptor sensitivity and decreases serotonin transmission, creating a vulnerable state in which dopamine overactivity and serotonin deficiency appear simultaneously. Because estrogen normally has a protective role, downregulating dopamine D2 receptors and promoting serotonin transmission, its abrupt decrease causes dual neurochemical instability. Sleep deprivation and social stress overactivate the HPA axis and worsen the mechanism.

Special mechanisms of late-onset cases: Along with age-related changes in the dopamine system with normal aging (decreased D2 receptor density, decreased dopamine synthesis), frontal-striatal circuit damage due to cerebrovascular disease can induce the manifestation of a schizoaffective clinical phenotype. Changes in antipsychotic metabolism in the elderly (prolonged half-life, altered protein binding) are also an important pharmacokinetic consideration.

Mechanism of cases with hypomania: A state in which mesolimbic dopamine overactivity milder than in a typical manic episode, accompanied by grandiosity, increased energy, and decreased sleep, simultaneously induces positive psychotic symptoms. This can be understood as a lower-severity version of the manic type (F25.0).


6. Symptoms

The symptoms of other schizoaffective disorder (F25.8) have the basic structure of coexisting schizophrenia symptoms and mood episodes, but show atypical features that do not fully meet the typical criteria of F25.0-F25.2.

Psychotic symptoms: Schizophrenia symptoms (auditory hallucinations, delusions, disorganized thinking, negative symptoms) may appear similarly to F25.0-F25.2. However, in atypical phenotypes, the duration, intensity, and content of symptoms may differ from the typical subtypes. For example, there are patterns in which schizophrenia symptoms persisting alone without a mood episode last less than 2 weeks, or in which psychotic symptoms appear mainly in tandem with mood episodes.

Atypical mood episodes: F25.8 may include cases in which a hypomanic episode (not meeting mania criteria, without functional decline) coexists with schizophrenia symptoms, cases in which depressive symptoms not meeting the criteria for a major depressive episode (subsyndromal depression) accompany schizophrenia symptoms, and cases in which the duration of the mood episode is shorter than the DSM-5 or ICD-10 criteria.

Symptom specificity of perinatal cases: In perinatal schizoaffective cases with postpartum onset, confusion, disorientation, abrupt mood swings (alternation of euphoria and dysphoria), insomnia, auditory hallucinations (especially with content about the newborn), and delusions (including commands to harm the newborn or that the newborn is a devil) may appear. This is an emergency requiring immediate evaluation and treatment, and risk assessment for newborn safety is also essential.

Symptom specificity of late-onset cases: Cases in which visual hallucinations are more prominent than auditory hallucinations, cases in which cognitive decline (memory, executive function) appears together with psychotic symptoms, and cases in which mood symptoms are expressed as subsyndromal depression rather than a depressive episode may be included among late-onset atypical schizoaffective cases.


7. Signs

The clinical signs of other schizoaffective disorder (F25.8) follow those of F25.0-F25.2, but because of atypicality, application of standard rating scales may be incomplete. Reconfirming organic causes and longitudinal monitoring of the course are especially important.

Psychiatric interview findings: Atypical symptom patterns may appear in the interview, and incomplete forms of mood symptoms (mild grandiosity, subsyndromal depression) are observed together with classic features of schizophrenia symptoms (first-person auditory hallucinations, thought insertion, etc.). In perinatal cases, confusion and disorientation may be prominent. In elderly cases, visual hallucinations and dementia-like cognitive decline may accompany.

Physical examination findings: Physical examination is especially important in atypical schizoaffective cases. Thyroid enlargement (thyroid dysfunction), Cushingoid signs (cortisol excess), autoimmune neurologic signs (seizures, movement disorders, autonomic abnormalities), and parkinsonian signs (Lewy body-related) should be carefully assessed. In perinatal cases, puerperal fever, eclampsia, etc. are excluded.

Neurocognitive assessment: Especially in late-onset cases, cognitive function assessment with the K-MMSE, MoCA, and neuropsychological batteries is essential and is used for differentiation from neurodegenerative disease and vascular cognitive impairment. Episodic memory, executive function, and language function are assessed systematically.

Rating scales: PANSS, YMRS, MADRS, and C-SSRS are applied as the basis, and in elderly patients the GDS (Geriatric Depression Scale) and CDR (Clinical Dementia Rating) are added. In perinatal cases, the EPDS (Edinburgh Postnatal Depression Scale) can also be consulted.


8. Screening

In other schizoaffective disorder (F25.8), exclusion of organic causes must be pursued more actively because of the atypical clinical picture. Because F25.8 is a diagnostic code applied after organic causes have been excluded, the differential diagnosis process is even more important.

Priority tests to exclude organic causes: These include brain MRI (brain tumor, cerebrovascular disease, temporal lobe lesions), EEG (temporal lobe epilepsy), thyroid function tests (TSH, FT4), adrenal function tests, blood vitamin B12 and folate, blood glucose, electrolytes, liver function, renal function, syphilis serology (RPR), and HIV testing. In elderly patients, cerebrovascular MRA is also considered to exclude vascular cognitive impairment.

Autoimmune encephalitis panel: In atypical schizoaffective cases, an autoimmune encephalitis panel including anti-NMDAR antibody, anti-LGI1 antibody, anti-CASPR2 antibody, and anti-GABA-B antibody is especially important. Autoimmune encephalitis can mimic a schizoaffective picture and is recoverable with appropriate immunotherapy.

Special tests for perinatal cases: Puerperal infection (fever, CBC, inflammatory markers), eclampsia (blood pressure, proteinuria, platelets), thyroid function (postpartum thyroiditis), and blood glucose abnormalities are excluded. Newborn safety assessment must also be performed immediately.

Clinical interview to establish the diagnosis: The criteria of F25.0-F25.2 are systematically reviewed with a structured interview using the SCID-5 or MINI. F25.8 is applied when these criteria are not fully met. The follow-up plan and reassessment schedule are set at the initial evaluation.


9. Diagnosis

Other schizoaffective disorder (F25.8) is established as a diagnosis by exclusion, applied to schizoaffective clinical phenotypes that do not fall under F25.0-F25.2 after systematic review of those criteria.

Principles of applying ICD-10 F25.8: After systematically reviewing the criteria for F25.0 (manic type), F25.1 (depressive type), and F25.2 (mixed type) and confirming that none applies, F25.8 is assigned if coexistence of schizophrenia symptoms and mood episodes is nevertheless clinically clear. It is advisable to use the code together with as detailed a clinical description as possible. For example, add descriptions such as "with hypomania," "perinatal onset," or "late-life onset."

Similar category in DSM-5: DSM-5 has no category that corresponds exactly to F25.8. In DSM-5, "Other Specified Schizophrenia Spectrum and Other Psychotic Disorder" is the most similar category, and it is recommended that the specific reason be stated.

Distinction from F25.9: F25.8 (other) is used when the schizoaffective clinical picture is clear but does not fit the typical subtype criteria, whereas F25.9 (unspecified) is used when there is insufficient information to determine the subtype. This distinction is not always clinically clear, so the aim should be a diagnosis of a typical subtype (F25.0-F25.2) rather than F25.8 or F25.9 whenever possible.

Longitudinal reassessment: The F25.8 diagnosis is regarded as provisional, and after sufficient follow-up (6 months to 1 year), reclassification to a typical subtype (F25.0-F25.2) or another psychiatric diagnosis (schizophrenia, bipolar disorder, psychotic depression) is attempted.


10. Treatment

Treatment of other schizoaffective disorder (F25.8) applies the treatment principles of F25.0-F25.2 according to the main type of clinical symptoms, but safety considerations suited to special clinical situations (perinatal, elderly, adolescent) must be made.

Basic pharmacotherapy principles: If psychotic symptoms are the main clinical problem, a second-generation antipsychotic is the first choice, and a mood stabilizer or antidepressant is added according to clinical symptoms. In cases with hypomania, treatment equivalent to F25.0 (manic type) (antipsychotic + mood stabilizer) is applied. In cases with subsyndromal depression, an antipsychotic alone or quetiapine (which includes an antidepressant effect) is tried first.

Treatment specificity in perinatal cases: During pregnancy or breastfeeding, fetal and newborn safety is the top priority in drug selection. In atypical schizoaffective cases during pregnancy, haloperidol has the most safety data, and among second-generation antipsychotics, olanzapine and quetiapine have relatively more safety data in pregnancy. During breastfeeding, quetiapine is considered relatively safe. Valproate carries a high risk of malformation in pregnancy, so caution is needed in women of childbearing potential. In severe postpartum states, ECT can be a safe and rapid treatment alternative.

Treatment specificity in elderly cases: In the elderly, start antipsychotics at 1/3-1/2 of the dose for young adults and increase slowly. Extrapyramidal symptoms and fall risk are high, so take care with dose adjustment. Risperidone, olanzapine, and quetiapine can be used at low doses, but use should be decided carefully, recognizing the increased mortality risk in elderly patients with dementia. Lithium requires caution in the elderly because of the high risk of toxicity with reduced renal function.

Psychosocial treatment: As with F25.0-F25.2, cognitive behavioral therapy, family psychoeducation, and social skills training should be provided in parallel. In perinatal cases, interventions to restore the mother-infant relationship and postpartum depression prevention programs are important.


11. Prognosis

The prognosis of other schizoaffective disorder (F25.8) is difficult to generalize because of the diversity of clinical phenotypes. Prognosis may differ greatly depending on the clinical situation included (perinatal, elderly, atypical presentation).

Prognosis of perinatal cases: Postpartum psychosis has a relatively good short-term prognosis when treatment is started quickly. Complete remission is often reached within 3-6 months. However, the risk of later developing bipolar disorder, schizoaffective disorder, or schizophrenia is high (especially when the postpartum psychosis is on the bipolar disorder spectrum), and the risk of recurrence in the next pregnancy reaches 25-50%. Careful counseling on balancing breastfeeding and maintenance medication is needed.

Prognosis of late-onset cases: Primary late-onset schizoaffective cases in which organic causes have been excluded can have symptoms controlled with appropriate antipsychotic use. However, when they are a prodrome of neurodegenerative disease such as dementia, the prognosis is poor and persistent cognitive decline appears. When associated with cerebrovascular disease, control of vascular risk factors is important for prognosis.

Prognosis of atypical presentation cases: The more a case can be reclassified into a typical subtype, the more it follows the prognostic characteristics of that subtype. Cases with hypomania may show a relatively good prognosis comparable to the manic type (F25.0). In cases that respond well to treatment, treatment effects similar to those of the typical subtypes can be expected.

Factors improving prognosis: Early diagnosis and treatment initiation, accurate exclusion of organic causes, appropriate drug selection for the main symptom type, maintained treatment adherence, and a strong social support network contribute to improved prognosis in all F25.8 cases.


12. Prevention

Prevention of other schizoaffective disorder (F25.8) is based on the prevention principles of F25.0-F25.2, but a tailored prevention plan suited to special clinical situations should be developed.

Prevention in perinatal cases: For women at high risk of postpartum psychosis or perinatal schizoaffective cases (bipolar disorder, prior history of perinatal psychosis, family history of schizoaffective disorder), establish a mental health monitoring plan from before pregnancy through the postpartum period. Prophylactic administration of a mood stabilizer or antipsychotic immediately after delivery may be considered in high-risk women. Sleep support and sleep protection through family sharing of night feedings are important. A newborn safety plan is established in advance.

Prevention in elderly cases: To prevent the onset of schizoaffective symptoms in the elderly, control of cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking), prevention of cerebrovascular disease, and avoidance of alcohol abuse are important. Thyroid function, vitamin B12, and folate levels are monitored regularly to prevent onset due to metabolic causes.

Relapse prevention and maintenance therapy: After symptoms stabilize, maintenance pharmacotherapy equivalent to that of the typical subtypes is continued. Use of LAI is considered to improve treatment adherence. A suicide prevention safety plan (safety planning) is established and updated regularly. Family psychoeducation strengthens the ability to recognize prodromal symptoms of relapse.

Prevention in atypical presentation cases: In atypical schizoaffective cases without organic causes, avoiding substance abuse, regular sleep, and stress management are important for preventing episodes. When a case is reclassified to a typical subtype through regular diagnostic reassessment, the prevention guidelines for that subtype are applied.


13. References

  1. Malaspina D, Owen MJ, Heckers S, et al. Schizoaffective disorder in the DSM-5. Schizophr Res. 2013;150(1):21-25. DOI: 10.1016/j.schres.2013.04.026. PMID: 23707642.

  2. Heckers S, Barch DM, Bustillo J, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res. 2013;150(1):11-14. DOI: 10.1016/j.schres.2013.04.039. PMID: 23707641.

  3. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin Psychiatry. 2003;64(11):1284-1292. DOI: 10.4088/jcp.v64n1103. PMID: 14658941.

  4. Murru A, Pacchiarotti I, Nivoli AM, et al. What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol. 2011;21(9):680-690. DOI: 10.1016/j.euroneuro.2011.03.010. PMID: 21482081.

  5. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry. 2000;157(2):172-178. DOI: 10.1176/appi.ajp.157.2.172. PMID: 10671383.

  6. Jäger M, Becker T, Weinmann S, Frasch K. Treatment of schizoaffective disorder — a challenge for evidence-based psychiatry. Acta Psychiatr Scand. 2010;121(1):22-32. DOI: 10.1111/j.1600-0447.2009.01424.x. PMID: 19522882.

  7. Nager A, Johansson LM, Sundquist K. Neighborhood socioeconomic environment and risk of postpartum psychosis. Arch Womens Ment Health. 2006;9(2):81-86. DOI: 10.1007/s00737-005-0108-6. PMID: 16400553.

  8. Pagel T, Baldessarini RJ, Franklin J, Baethge C. Characteristics of patients diagnosed with schizoaffective disorder compared with schizophrenia and bipolar disorder. Bipolar Disord. 2013;15(3):229-239. DOI: 10.1111/bdi.12057. PMID: 23528001.

  9. Cascade EF, Kalali AH, Buckley P. Treatment of schizoaffective disorder. Psychiatry (Edgmont). 2009;6(3):15-17. PMID: 19724741.

  10. Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders. J Clin Psychiatry. 2007;68(6):899-907. DOI: 10.4088/jcp.v68n0612. PMID: 17592915.